Publicaciones en las que colabora con NOEMI PUIG MORON (32)

2023

  1. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

    Cancers, Vol. 15, Núm. 5

2022

  1. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

    Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Genetic complexity impacts the clinical outcome of follicular lymphoma patients

    Blood Cancer Journal

2020

  1. A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients

    Journal of Molecular Diagnostics, Vol. 22, Núm. 1, pp. 60-71

  2. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  3. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation

    Bone Marrow Transplantation, Vol. 55, Núm. 2, pp. 419-430

  4. Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder

    Leukemia and Lymphoma

  5. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients

    British Journal of Haematology, Vol. 189, Núm. 4, pp. 718-730

  6. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

  7. Reply to Brown et al: ‘Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis’

    Leukemia and Lymphoma

  8. STAT3 and STAT5B mutations in T/NK-cell chronic lymphoproliferative disorders of large granular lymphocytes (LGL): Association with disease features

    Cancers, Vol. 12, Núm. 12, pp. 1-20

2019

  1. Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas

    Blood Cancer Journal, Vol. 9, Núm. 7

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

  2. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study

    Annals of Hematology, Vol. 97, Núm. 3, pp. 475-484

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: A whole-exome analysis of abnormalities leading to transformation

    Blood Cancer Journal, Vol. 7, Núm. 8

  3. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

    Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751

  4. Primary diffuse large B cell lymphoma of the uterine cervix successfully treated by combined chemotherapy alone

    Medicine (United States), Vol. 96, Núm. 19

  5. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy*

    Leukemia and Lymphoma, Vol. 58, Núm. 5, pp. 1144-1152